It gives top daily,weekly and monthly Gainers/Losers of BSE indices on % basis in descending order. Click on company name to get the company profile page.
Dr. Reddy's Laboratories announced the launch of its injectable semaglutide under the brand name Obeda®, marking an important step in expanding access to advanced GLP‑1 receptor agonist–based therapy for the management of type 2 diabetes in India.
Dr. Reddy's has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company's Day‑1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India.
FOR GRIEVANCE MAIL TO invgrieviss@iseindia.com
BSE EQUITIES : INB011077733 | NSE F&O EQUITIES : INF231077737 | NSE CASH MARKET : INB231077737 | NSE CURRENCY DERIVATIVES : INE231077737 | MCX-SX : INE261077737
ISS Enterprise Limited [Erstwhile: ISE Securities & Services Limited], a wholly owned subsidiary of Inter-connected Stock Exchange of India Ltd. (ISE)
© 2013 ISS Enterprise Limited [Erstwhile: ISE Securities & Services Limited]. All rights reserved.
Designed, developed & powered by C-MOTS Infotech (ISO 9001:2008 certified)